DoH Policies screened during the period: 1st April 2021-30th June 2021
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.
Documents
- NICE Technology Appraisal TA680 - Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (PDF 341KB)
- NICE Technology Appraisal TA681 - Baricitinib for treating moderate to severe atopic dermatitis (PDF 342KB)
- NICE Technology Appraisal TA682 - Erenumab for preventing migraine (PDF 340KB)
- NICE Technology Appraisal TA683 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (PDF 343KB)
- NICE Technology Appraisal TA684 - Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (PDF 341KB)
- NICE Technology Appraisal TA688 - Selective internal radiation therapies for treating hepatocellular carcinoma (PDF 513KB)
- NICE Technology Appraisal TA685 - Anakinra for treating Still’s disease (PDF 623KB)
- NICE Public Health Guideline NG146 - Workplace health: long-term sickness absence and capability to work (PDF 562KB)
- NICE Technology Appraisal TA687 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (review of TA593) (PDF 512KB)
- Allied Health Professions (AHP) Education Commissioning Plan (PDF 856KB)
- NICE Public Health Guideline PH43 - Hepatitis B and C testing: people at risk of infection (PDF 514KB)
- The Health Protection (Coronavirus, Wearing of Face Coverings) Regulations (Northern Ireland) 2020 and all applied amendments. (PDF 397KB)
- Substance Use Strategy Consultation Document (PDF 711KB)
- NICE Technology Appraisal TA698 - Acalabrutinib for treating chronic lymphocytic leukaemia (PDF 612KB)
- NICE Technology Appraisal TA691- Avelumab for untreated metastatic Merkel cell carcinoma (part review of TA517) (PDF 512KB)
- NICE Technology Appraisal TA693 - Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer (PDF 516KB)
- NICE Technology Appraisal TA695 - Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (part review of TA657) (PDF 513KB)
- NICE Technology Appraisal TA694 - Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (PDF 514KB)
- NICE Technology Appraisal TA692 - Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (review of TA519) (PDF 512KB)
- NICE Technology Appraisal TA696 - Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (PDF 624KB)
- NICE Technology Appraisal TA697 Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (PDF 607KB)
- NICE Technology Appraisal TA698 - Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (PDF 514KB)
- NICE Technology Appraisal TA699 - Ofatumumab for treating relapsing multiple sclerosis (PDF 512KB)
- NICE Technology Appraisal TA704 – Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies (PDF 623KB)
- NICE Technology Appraisal TA705 – Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (PDF 513KB)
- NICE Clinical Guideline NG151 - Colorectal cancer (updates and replaces CG131 and TA93) (PDF 514KB)
- The Health Security (EU Exit) Regulations 2021 (PDF 490KB)
- Establishment of a regional Care and Justice Campus (PDF 923KB)
- Covid Certification Service (PDF 852KB)